Presentation: Severe cutaneous allergic reactions in Brazil: New risk alleles to be identified in our population? (WAO International Scientific Conference 2014)

Tuesday, 9 December 2014: 10:20 - 10:40

Exhibition Hall-Poster Area (Sul America)

Maria Ines Perelló, MD , Internal Medicine, State University of Rio De Janeiro, Rio de Janeiro, Brazil

Camila M. Filgueiras, MD , Allergy and Immunology, State of University of Rio De Janeiro, Rio de Janeiro, Brazil

Fernanda Marques Conceição, MD , Allergy and Immunology, State University of Rio De Janeiro, Rio de Janeiro, Brazil

Natalia Rocha Estanislau, MD , Allergy and Immunology, State University of Rio De Janeiro, Rio de Janeiro, Brazil

Denise Lacerda Pedrazzi, MD , Internal Medicine, State University of Rio De Janeiro, Rio de Janeiro, Brazil

AssunÇao De Maria Gusmao Ferreira Castro, MD , Alergia e Imunologia Dermatológica, Instituto De Dermatologia PROF Rubem David Azulay, Rio de Janeiro, Brazil

Sonia Conte Caracciolo Costa, MD , Allergy and Immunology, State of University of Rio De Janeiro, Rio de Janeiro, Brazil

Eduardo Costafsilva, MD, MSc, PhD , Asthma Comission, Brazillian Association of Allergy and Immunology, Rio de Janeiro, Brazil

Background:

Severe cutaneous allergic reactions (SCAR) have a wide range of severity and clinical manifestations. Some risk alleles are known in specific populations. The aim of the study was to describe the clinical and laboratory profile of patients with SCAR, treated at a university hospital in Rio de Janeiro.

Methods:

This is a retrospective cross-sectional study. Clinical and laboratory data, including HLA typing, of patients with SCAR identified between March/2011 and July/2014 by pharmacologic surveillance, weekly done by our Service, were reviewed.

Results:

Twenty-three cases of SCAR were identified: 12 DRESS/DIHS, 1 overlap DRESS/AGEP and 10 SJS/TEN. Sixteen patients (70%) were female, the median age was 41 years (IQR=26-50). The aromatic anticonvulsivants were implicated in the etiology in 73% of cases, followed by antibiotics (30%). All patients with DRESS/DIHS exhibited cutaneous, systemic and laboratory characteristic changes of this syndrome. Patients with SJS/TEN had fever and mucosal involvement, 20% had neurological abnormalities and no one organ involvement or ocular complications. Eight (66%) patients with DRESS had late reactivation of disease. There was 1 death due to refractory cardiac insufficiency. During the 1^styear of outpatient follow-up, we found autoimmune changes in 21% of patients. Reactions to others drugs following diagnosis occurred in 2 patients with DRESS/DIHS, 1 patient with SJS/TEN had solar urticaria and another one with DRESS/DIHS developed dermographism. All patients with DRESS/DIHS were treated with corticosteroids, with an average of 108 days (9-180) of treatment. Eight out of 10 patients with SJS/TEN used corticosteroids with good response. IGIV was used in 1 patient with SJS/TEN and associated with steroids in 1 patient with DRESS/DIHS. We identified the known relationship between carbamazepine (CBZ) and HLA-A*31:01 in 2 patients with DRESS and allopurinol and HLA-B*58:01 in 2 patients (one SJS/TEN and one overlap DRESS/AGEP). Interestingly, we found the same alleles in 3 patients with DRESS caused by phenytoin (HLA-A*23 and HLA-B*53) and in 3 (DRESS) with carbamazepine (HLA-A*74 and HLA-B*15). None of them were family related.

Conclusions:

This study confirmed the main clinical and laboratory features of SCAR. The correct and early diagnosis of these reactions allowed the effective management and ambulatory monitoring, with a good outcome in most cases. The HLA typing can corroborate the diagnosis in 4 cases. The repetition of still not described alleles in our patients deserves larger studies to identify if these alleles are associated with higher risk of SCAR in our population.

3004 Severe cutaneous allergic reactions in Brazil: New risk alleles to be identified in our population?